Loading company
Galmed Pharmaceuticals Ltd.
EOCN · Nasdaq
$3.54-2.5%Sep 29 close
- 1M
- -15.0%
- 6M
- -6.8%
- 1Y
- -67.9%
- 5Y
- -99.9%
EOCN · Nasdaq
$3.54-2.5%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$2.7M | -$2.5M | -9.14% |
| Profit per share | -$0.80 | -$0.95 | +15.52% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Galmed Pharmaceuticals Ltd. has no earnings call transcript available.